REZUROCK

This brand name is authorized in United States. It is also authorized in Austria, Canada, Estonia, Lithuania.

Active ingredients

The drug REZUROCK contains one active pharmaceutical ingredient (API):

1	Belumosudil UNII 6MX7XE1M0U - BELUMOSUDIL MESYLATE
	Belumosudil is a selective Rho-associated, coiled-coil containing protein kinase-2 (ROCK2) inhibitor that mediates signalling in immune cellular function and fibrotic pathways.
	Read more about Belumosudil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REZUROCK Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
REZUROCK Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA48		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA48

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02526115
EE	Ravimiamet	3148590, 3148602
LT	Valstybinė vaistų kontrolės tarnyba	1106348, 1106349
US	FDA, National Drug Code	79802-200